Brief: BioArctic Study Results From Phase 1 Studies With Exidavnemab

BioArctic AB

27/08/2024 07:18

Aug 27 (Reuters) - BioArctic AB  BIOAb.ST :
    * STUDY RESULTS FROM PHASE 1 STUDIES WITH EXIDAVNEMAB
PUBLISHED IN
THE JOURNAL OF CLINICAL PHARMACOLOGY
    * EXIDAVNEMAB WAS GENERALLY WELL-TOLERATED
    * HALF-LIFE OF APPROXIMATELY 30 DAYS
    * LOOKING FORWARD TO STARTING PHASE 2A STUDY LATER THIS YEAR

Source text for Eikon:  ID:nWkrbtspVb 
Further company coverage:  BIOAb.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))